As the demand for COVID vaccines decreases worldwide, Moderna is planning to release a RSV vaccine, pending U.S. approval.
The drugmaker is optimistic about higher sales with new vaccines and a little help from AI in the coming years.
Moderna had plenty to announce starting with COVID-19, where the company trumpeted its next-gen, refrigerator-stable vaccine for the ... year-to-date high closing price of $115.44.
Do you have questions surrounding COVID-19, the vaccine and impacts on our communities? ABC13 is committed to finding answers and connecting you with resources. Man deliberately gets 217 Covid ...
News that the Biden administration is planning to push for Americans to get the updated COVID vaccines this fall caused several vaccine manufacturers' stock prices to rise Monday. Moderna CEO ...
Moderna will chart its post-Covid ... vaccines in Phase 3, and three more moving toward Phase 3, we have built a very large and diverse portfolio addressing significant unmet medical needs ...
It also had plans to start filling doses of its COVID vaccine in the continent as early as 2023. However, Moderna has not received any vaccine orders for Africa since 2022 amid waning demand ...
One of the world’s top vaccine-makers is partnering with a major AI company to advance medicine — and its chief executive is excited. Moderna and OpenAI announced an ongoing partnership ...